$1.07 Trillion is the total value of Casdin Capital, LLC's 31 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 38.5% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
NVTA | Buy | INVITAE CORP | $90,202,118,000 | +174968.2% | 3,838,388 | +74.5% | 8.44% | +49.2% |
BPMC | Buy | BLUEPRINT MEDICINES CORP | $88,670,200,000 | +130424.0% | 940,000 | +10.8% | 8.30% | +11.2% |
CDXS | Buy | CODEXIS INC | $86,519,885,000 | +208015.6% | 5,073,780 | +150.6% | 8.10% | +77.3% |
SRPT | Buy | SAREPTA THERAPEUTICS INC | $50,903,250,000 | +139924.9% | 335,000 | +9.8% | 4.76% | +19.3% |
BLUE | Buy | BLUEBIRD BIO INC | $47,382,000,000 | +84142.2% | 372,500 | +4.2% | 4.44% | -28.2% |
ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $47,164,000,000 | +113315.9% | 650,000 | +46.1% | 4.42% | -3.3% |
MGTA | Buy | MAGENTA THERAPEUTICS INC | $44,296,035,000 | +101648.1% | 3,003,121 | +13.6% | 4.15% | -13.3% |
AGIO | Buy | AGIOS PHARMACEUTICALS INC | $24,690,600,000 | +109189.1% | 495,000 | +47.8% | 2.31% | -6.9% |
ADPT | New | ADAPTIVE BIOTECHNOLOGIES COR | $20,100,347,000 | – | 463,125 | +100.0% | 1.88% | – |
GRTS | Buy | GRITSTONE ONCOLOGY INC | $19,717,800,000 | +132198.7% | 1,770,000 | +58.0% | 1.85% | +12.8% |
SGMO | Buy | SANGAMO THERAPEUTICS INC | $16,478,100,000 | +159835.0% | 1,530,000 | +41.7% | 1.54% | +36.2% |
FIXX | Buy | HOMOLOGY MEDICINES INC | $14,579,650,000 | +150112.8% | 745,000 | +112.9% | 1.36% | +28.0% |
ALEC | Buy | ALECTOR INC | $10,189,059,000 | +164319.2% | 551,039 | +66.5% | 0.95% | +40.1% |
TWST | New | TWIST BIOSCIENCE CORP | $8,703,000,000 | – | 300,000 | +100.0% | 0.82% | – |
DNLI | Buy | DENALI THERAPEUTICS INC | $8,304,000,000 | +357522.7% | 400,000 | +300.0% | 0.78% | +204.7% |
STOK | New | STOKE THERAPEUTICS INC | $2,479,450,000 | – | 85,000 | +100.0% | 0.23% | – |
TPTX | New | TURNING POINT THERAPEUTICS I | $2,442,000,000 | – | 60,000 | +100.0% | 0.23% | – |
ORTX | New | ORCHARD THERAPEUTICS PLCadr | $1,399,000,000 | – | 100,000 | +100.0% | 0.13% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
CODEXIS INC | 22 | Q3 2023 | 8.1% |
SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-05-17 |
13F-HR | 2024-05-15 |
4 | 2024-05-15 |
4 | 2024-05-02 |
SC 13G | 2024-04-18 |
SC 13D/A | 2024-04-08 |
4 | 2024-03-28 |
3 | 2024-03-25 |
4 | 2024-03-25 |
4 | 2024-03-20 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.